Reference health
Determinants of buildup of the toxic dopamine metabolite<scp>DOPAL</scp>in Parkinson's disease
50/50 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 50 checked references that resolve
resolves10.1074/jbc.M111.249532
Oxidation of 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopaminergic Metabolite, to a Semiquinone Radical and an ortho-Quinone
resolves10.1038/sj.jcbfm.9600276
Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease
resolves10.1124/mol.62.4.795
Kinetics and Crystal Structure of Catechol-O-Methyltransferase Complex with Co-Substrate and a Novel Inhibitor with Potential Therapeutic Application
resolves10.1016/S0006-8993(03)03354-7
3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson’s disease pathogenesis
resolves10.1016/S0161-813X(03)00090-1
Neurotoxicity of MAO Metabolites of Catecholamine Neurotransmitters: Role in Neurodegenerative Diseases
resolves10.1007/s00401-007-0303-9
Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine
resolves10.1523/JNEUROSCI.0319-07.2007
Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration
resolves10.1007/BF01485901
Verteilung Von Noradrenalin Und Dopamin (3-Hydroxytyramin) Im Gehirn Des Menschen Und Ihr Verhalten Bei Erkrankungen Des Extrapyramidalen Systems
resolves10.1124/pr.56.3.1
Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine
resolves10.1073/pnas.1220399110
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease
resolves10.1046/j.1471-4159.1998.70051973.x
Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice
resolves10.1016/j.nbd.2003.09.001
ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia
resolves10.1007/s10571-011-9780-4
Stress, Allostatic Load, Catecholamines, and Other Neurotransmitters in Neurodegenerative Diseases
resolves10.1007/s002100100426
Kinetic model for the fate of 6-[ 18 F]fluorodopamine in the human heart: a novel means to examine cardiac sympathetic neuronal function
resolves10.1111/j.1468-1331.2010.03246.x
Catechols in post-mortem brain of patients with Parkinson disease
resolves10.1093/brain/aws055
Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathies
resolves10.1111/j.1471-4159.2012.07924.x
Vesicular uptake blockade generates the toxic dopamine metabolite 3,4‐dihydroxyphenylacetaldehyde in <scp>PC</scp>12 cells: relevance to the pathogenesis of Parkinson's disease
resolves10.1007/s00702-010-0509-1
Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease
resolves10.1007/s12035-009-8059-y
Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons
resolves10.1111/j.1471-4159.2008.05568.x
Reduced vesicular storage of dopamine exacerbates methamphetamine‐induced neurodegeneration and astrogliosis
resolves10.1016/0378-4347(93)E0430-X
Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection
resolves10.1373/clinchem.2009.139709
Contamination of the Norepinephrine Prodrug Droxidopa by Dihydroxyphenylacetaldehyde
resolves10.1016/S0169-328X(01)00120-6
3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson’s disease pathogenesis
resolves10.1111/j.1745-7254.2005.00003.x
Intracellular dopamine oxidation mediates rotenone-induced apoptosis in PC12 cells
resolves10.1196/annals.1344.031
Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70
resolves10.1124/pr.59.2.1
Neurotoxicity and Metabolism of the Catecholamine-Derived 3,4-Dihydroxyphenylacetaldehyde and 3,4-Dihydroxyphenylglycolaldehyde: The Role of Aldehyde Dehydrogenase
resolves10.1016/1055-8330(95)90016-0
An endogenous dopaminergic neurotoxin: Implication for Parkinson's disease
resolves10.1006/exnr.1998.7008
Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's Disease
resolves10.2967/jnumed.109.070094
In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with <sup>18</sup>F-AV-133
resolves10.1371/journal.pone.0015251
The Neurotoxicity of DOPAL: Behavioral and Stereological Evidence for Its Role in Parkinson Disease Pathogenesis
resolves10.1126/science.276.5321.2045
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
resolves10.1021/tx700248y
Lipid Peroxidation Products Inhibit Dopamine Catabolism Yielding Aberrant Levels of a Reactive Intermediate
resolves10.1021/tx9000557
Protein Reactivity of 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite, Is Dependent on Both the Aldehyde and the Catechol
resolves10.1016/j.tiv.2008.04.019
Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism
resolves10.1038/ng.485
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease
resolves10.1016/S0022-3565(24)39240-7
Inhibition of Brain Vesicular Monoamine Transporter (VMAT2) Enhances 1-Methyl-4-phenylpyridinium Neurotoxicity In Vivo in Rat Striata
resolves10.1523/JNEUROSCI.1495-09.2009
Nonmotor Symptoms of Parkinson's Disease Revealed in an Animal Model with Reduced Monoamine Storage Capacity
resolves10.1038/jcbfm.2011.63
Distribution of Vesicular Monoamine Transporter 2 Protein in Human Brain: Implications for Brain Imaging Studies
resolves10.1016/j.nbd.2012.05.012
Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons
resolves10.1016/S0896-6273(00)80419-5
Knockout of the Vesicular Monoamine Transporter 2 Gene Results in Neonatal Death and Supersensitivity to Cocaine and Amphetamine
resolves10.1371/journal.pone.0031522
Neurodegeneration and Motor Dysfunction in Mice Lacking Cytosolic and Mitochondrial Aldehyde Dehydrogenases: Implications for Parkinson's Disease
resolves10.1073/pnas.93.7.2696
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.
The 2 references without a DOI — listed, not checked
no DOI — not checkedDopamine transporter and vesicular monoamine transporter knockout mice: implications for Parkinson's disease
no DOI — not checkedPET measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1111/jnc.12345"><img src="https://citestamp.com/citestamped/10.1111/jnc.12345/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1111/jnc.12345)